Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction (Q45884966)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction |
scientific article |
Statements
1 reference
Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction (English)
1 reference
Enyu Ding
1 reference
Huimin Hu
1 reference
Bradley L Hodges
1 reference
Felicia Migone
1 reference
Delila Serra
1 reference
Fang Xu
1 reference
Yuan-Tsong Chen
1 reference
Andrea Amalfitano
1 reference
1 April 2002
1 reference
1 reference
5
1 reference
4
1 reference
436-446
1 reference
Identifiers
1 reference
1 reference